RT Journal Article
SR Electronic
T1 Streamlined quantification of absolute MBF at rest and stress with flurpiridaz F-18 injection PET in normal subjects and patients with coronary artery disease (CAD)
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1114
OP 1114
VO 52
IS supplement 1
A1 Huang, Sung-Cheng
A1 Dahlbom, Magnus
A1 Maddahi, Jamshid
A1 Truong, David
A1 Lazewatsky, Joel
A1 Washburn, Dana
A1 Schelbert, Heinrich
A1 Czernin, Johannes
A1 Phelps, Michael
YR 2011
UL http://jnm.snmjournals.org/content/52/supplement_1/1114.abstract
AB 1114 Objectives Flurpiridaz F-18 is a new PET myocardial perfusion tracer that is currently undergoing clinical evaluation. We investigated the feasibility of streamlined quantification of rest (R) and stress (S) myocardial blood flows (MBFs) and coronary flow reserve (CFR) with this tracer for clinical use in normal subjects (NS) and CAD patients (Pts). Methods Ten Pts [6 NS; 4 with CAD (>50% stenosis) and reversible defects] received flurpiridaz F-18 injection at R and at peak adenosine S followed by 10-min dynamic scan. The R-S imaging was same-day in 5 Pts and separate-day in 5 Pts. R and S polar maps (PM) were generated from summed image ( 0.5-2 min) and the 3 coronary territories (LAD, RCA, LCX) and the left ventricular blood pool (LV) were defined. Reversible defects were manually assigned on PM, from which time activity curves (TACs) were generated. A compartment model that included an irreversible uptake constant (K) and a spillover from blood pool was used to fit the tissue TACs (0-2 min). LV TAC was the input function. Partial volume effect of tissue was estimated as (1-spf), with spf denoting the blood spillover fraction obtained from fitting. The first-pass extraction fraction for flurpiridaz F-18 was assumed to be 0.94 based on pre-clinical studies. CFR was calculated as S/R MBF. Results MBF and CFR were compared between 18 normal territories ( in 6 NS) and 5 reversible defect regions (Table, * indicates p<0.05). The results agree with the published results using N-13 ammonia PET. Conclusions Quantification of MBF using flurpiridaz F-18 injection cardiac PET can be streamlined in clinical settings to give robust MBF results